Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided...
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided...
ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
STOCKHOLM, SWEDEN / ACCESSWIRE / February 23, 2024 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB ("iZafe Group") is pleased to...
"MMJ International Holdings has manufactured a botanical extract in a final dose form gel cap and will investigate its novel...
Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic 1 basisFull-Year revenues...
WINNIPEG, Manitoba, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”)...
BASKING RIDGE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
REDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing...
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxisIRVINE, Calif., Feb. 22, 2024 (GLOBE...
Predictive Precision Medicine Platform (PPMP) utilized to enrich program for clinically responding patients and reduce the risk, time, and cost...
TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth...
CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies...
Company implementing a series of cost-savings measures designed to extend Salarius’ expected cash runway into the first half of 2025...
Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND...
The Phase 1/2 trial will assess the efficacy and safety of BNT316/ONC-392 in combination with the radioligand therapy lutetium (177Lu)...
BOSTON and LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims...
Two “Compassionate Use” Expanded Access Programs (EAPs) provided access to treatment with CNM-Au8 to more than 250 people living with...
Neurological diseases, which affect up to 16 million people over 18 years old in the US, are the leading cause...
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s...
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing...